<DOC>
	<DOC>NCT00803816</DOC>
	<brief_summary>Study efficacy of everolimus on course of uveitis: - obtain quiescence of inflammation after start of treatment - duration to obtain quiescence of inflammation - number of patients with quiescence of inflammation</brief_summary>
	<brief_title>Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A</brief_title>
	<detailed_description>occurence of new complications from uveitis - course of visual acuity (LogMAR): percentage of patients with visual loss of 10 or more numbers on ETDRS as compared to baseline - change of recurrence rate as compared to time before everolimus treatment - occurence of recurrence after obtaining remission with everolimus treatment - duration to occurence of recurrence o number of patients with recurrence - corticosparing effect from everolimus - number of patients without topical corticosteroids; number of patients with reduced topical corticosteroids (&lt;3x/daily) - number of patients without systemic corticosteroids; number of patients with reduced systemic corticosteroids (&lt;10mg/daily) - efficacy of uveitis within 12 months - maintenance of remission after withdrawel of everolimus treatment at 12 months o course of cystoid macula edema (FLA, OCT)</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>endogenous intermediate or posterior uveitis no quiesence in previous 3 months under systemic and topical steroids or systemic cyclosporine A indication for steroid sparing therapy uveitis related vision threating complications negative pregnancy test effective contraception Ophthalmic parameters: silicone oil in anterior chamber of both eyes para or intraocular corticosteroid injections within previous 8 weeks opacities of optic media that obscure visualization of anterior or posterior eye segments General parameters: requirement for combined immunosuppression for systemic immunemediated disease contraindication against everolimus or cyclosporine A positive tuberculine test (GT 10 currently immunosuppressive therapy with immunosuppressive drug other than cyclosporine poor compliance known intolerance to medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>endogoneous</keyword>
	<keyword>posterior</keyword>
	<keyword>intermediate</keyword>
</DOC>